Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Inclusion Criteria: * Participant has a relapsing form of Multiple Sclerosis (MS); diagnosis of MS is in accordance with the McDonald criteria * Participant is eligible for interferon therapy * Participant is between 18 and 60 years old * Participant has an Expanded Disability Status Scale (EDSS) \< 6.0. * Participant is willing to follow study procedures * Participant has given written informed consent * Female participants must be neither pregnant nor breast-feeding, and must lack childbearing potential, as defined by either: * Being post-menopausal or surgically sterile, or * Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. * Confirmation that the participant is not pregnant must be established by a negative serum or urinary hCG test within 7 days prior to start of study treatment. A pregnancy test is not required if the participant is post-menopausal or surgically sterile. Exclusion Criteria: * Participant has a Clinically Isolated Syndrome (CIS), Primary Progressive MS, or Secondary Progressive MS without superimposed relapses. * Participant had any prior interferon beta therapy (either beta-1b or beta-1a) * Participant has an ongoing MS relapse. * Participant received any other approved disease modifying therapy for MS (e.g. glatiramer acetate) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1(SD1). * Participant had prior use of cladribine or has previously received total lymphoid irradiation. * Participant received oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 30 days of SD1. * Participant received intravenous immunoglobulins or underwent plasmapheresis within the 6 months prior to SD1. * Participant received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to SD1. * Participant requires chronic or monthly pulse corticosteroids during the study. * Participant received any investigational drug or experimental procedure within 12 weeks of SD1. * Participant has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase \> 2.5 times the upper limit of the normal values. * Participant has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal. * Participant suffers from current autoimmune disease. * Participant suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol. * Participant has a known allergy to IFN or the excipients.